Meet the 25 Year-Old Behind L.A.'s Plan to Test Every Resident for COVID-19

Rachel Uranga

Rachel Uranga is dot.LA's Managing Editor, News. She is a former Mexico-based market correspondent at Reuters and has worked for several Southern California news outlets, including the Los Angeles Business Journal and the Los Angeles Daily News. She has covered everything from IPOs to immigration. Uranga is a graduate of the Columbia School of Journalism and California State University Northridge. A Los Angeles native, she lives with her husband, son and their felines.

Meet the 25 Year-Old Behind L.A.'s Plan to Test Every Resident for COVID-19

Fred Turner, the 25-year-old founder of Curative Inc., is the man behind L.A.'s push to bring universal testing to the region. But, he has bigger plans.

Turner, an Oxford dropout, just landed a deal with the Air Force to test military worldwide and he's now eyeing national expansion for his startup. By the end of this month, the company he started months ago is expected to pump out more than a million test kits a week.

"We are a strange company because our goal is to essentially put ourselves out of business," Turner said.


Turner, who was named UK Young Engineer of the Year at age 17 when he built a DNA machine from his bedroom to figure out why his brother had red hair and he had brown hair, turned his focus to coronavirus in January. He upended his life as head of Shield Bio, which sought to eliminate sepsis, and moved to Southern California after a local venture capitalist connected him with a lab that he could build out for COVID-19 testing.

Curative Inc. was born.

Curative, Inc. Founder Fred Turner is the man behind L.A.'s push to bring universal testing to the region.

For weeks he lived in hotels as he created what has become the backbone of testing in America's second largest city. The company, one of the few saliva-based tests that have gotten emergency approvals from the FDA, has a 10% false negative rate, according to their own non-peer reviewed studies. Turner argues the rate is better than most of the nasal swab testing out there and oral tests, which can be self-administered, are the only way the country can reopen quickly.

He is now operating two labs, one in San Dimas another in Washington D.C., with plans for several more across the nation. Meanwhile, the rest of the country is watching to see if Los Angeles' promise of universal testing meets the expectations with some already complaining about the difficulty of securing an appointment.

dot.LA: Curative is responsible for 95% of Los Angeles COVID-19 tests. Can you meet the demand for universal testing?

Curative, Inc. Founder Fred Turner: We will be able to fulfill demand. There's more infrastructure that needs to be put in place. With the collection site, the mayor's office has been working hard to scale those up and make sure that the collection site infrastructure is in place. On the lab side, we definitely have enough capacity to serve the area.

In (the San Dimas) lab we have capacity for about 20,000 per day. We're going to be scaling this lab up to 30,000 over the next week or so, eventually, probably slightly more than that.

Ultimately, the goal is to do as many tests as we need to reopen the country and I think we've had many different estimates of how many that might be. I've heard estimates (that it will take) as high as five million tests a day to reopen, but the current supply chain is nowhere near going to be able to keep up with that. The next goal we are shooting for is a million tests a week by about mid-May, end of May.

If we're testing more people will that strain the turnaround time? Right now, I understand it's about 24 to 72 hours. Can you take it down to several hours or even minutes?

We are always aiming to push it down. I think it can be pushed under 24 hours, but we tend to focus more on scaling it up at that point. I think 24 hours is around optimal as you bring on more capacity. We're obviously being careful to match the capacity coming into the lab against the turnaround.

Curative is one of the few companies that the FDA has provided emergency approval for use of a saliva test. Do you think this is the answer to universal testing nationally?

Oral fluids is the technical term, which is slightly different from saliva. Our protocol involves having the person cough first, which releases virus from the upper and lower respiratory tract. Some of that is then caught in the saliva, and also viruses in the saliva. The idea is you're effectively sampling multiple sites at once, which we think gives a slight increase in the sensitivity of the testing.

Self-collected sampling has got to be the way forward. There's just no way that we can do a million nasal pharyngeal swabs, or we call them 'brain swabs,' it's just not practical. We don't have the medical staff, and as a country we just can't do that many swabs. And so the way forward is going to be self collection. That's the only thing we can do at scale.

Covid-19 Oral Fluid Test Kit Instructions www.youtube.com

Curative recently secured a contract with the Department of Defense. What's next?

We haven't settled on the exact number, but we will be in a large number of states. That is the plan, building out the infrastructure for this kind of testing. We can take the L.A. model and scale it across the country. We have a version of the drive-thru software that other cities and states can take. We have all the training material. We have a team that fly around the country setting up these drive-thru sites. We have really tried to make a plug-and-play package where cities and states that want to launch drive-thru testing, we have everything they need.

Is Los Angeles a testing ground and a proving ground for national efforts?

Yeah, I think Mayor Garcetti has definitely demonstrated what can be done if the city moves very quickly to build out the infrastructure, I do think the drive-thru testing, walk through testing is going to be an essential component of this.

It's just much faster to get the samples to the lab than shipping it out and then shipping it back again. The infrastructure piece is critical for getting these tests out there and we're working with several other states now on building out a similar infrastructure. Some of them have existing programs that we would be plugging into and expanding, and some of them are looking to roll out their own similar programs. You can test a lot more people with the oral tests with far fewer staff.

What are the challenges with the supply chain in terms of making your tests more widely available?

We need more plastic, more robots, more people. Most of the components that go into these tests are just already maxed out in their production capacity. And so we've been throwing online a bunch of internal production, such as injection molding to make our swab kit tubes, as well as bringing on other sources of similar materials that are not being used for COVID-19 testing and validating them for COVID. So for the swabs, for example, we use a swab type that is usually used for testing clean rooms. It works just as well for COVID testing, but nobody else is using it for that purpose.

We don't want to be competing with other people, stopping them from getting access to resources. We want to bring on new supply so it's not a zero- sum game, and the total amount of tests will increase. But, I think distribution is going to be a bigger bottleneck over the next month. Los Angeles has done a fantastic job in building out infrastructure and collection. That needs to happen now across the whole country.

What would it take to meet national demand?

It would take a network of multiple labs that we are calling gigalabs that can process 50,000 to 100,000 tests a day across the country and a significant scale up in the production of the physical components that go into the tests. We've been investigating lab sites in a few states, something central like Texas or Colorado.

Are you concerned that you have too high of a false negative rate at 10%?

All COVID tests will have false negative rates. In our studies, we demonstrated that the sensitivity is at least as good if not better than the nasal pharyngeal swab tests. So, there will definitely be false negatives as there will be in every test, but we think the data supports us having a low rate of false negatives. The sensitivity is about 90%.

When you include all patients, the nasal pharyngeal came in at about 79%. A new (non-peer reviewed) Yale study shows a higher sensitivity from saliva and all fluids than the nasal pharyngeal. I don't think we have the evidence to say that we're better yet, but we have the evidence to say that we're at least equivalent. The ease of doing oral tests and the accessibility is obviously significantly better. We're not using PPE. We're not exposing healthcare workers. It's just a much easier test to roll out that people can test themselves.

File:Florida National Guard (49677710741).jpg - Wikimedia Commons upload.wikimedia.org

At one point, Curative was attempting to roll out at-home testing and then had to pull back after FDA warnings. Will you be making home testing kits again?

I can't give a time estimate but we are actively working with the FDA right now. I think their concern is "can people adequately collect the sample, or will they do it wrong, and then get a negative test result," which is incorrect. Our plan is to use telemedicine observation. What we've seen in our clinical studies is that if you give people the chance to do it wrong, they will do it wrong. In fact when you have somebody observing, they read the instructions better and they collect a better sample. We're still working on the pricing and potentially looking at whether there is federal or state reimbursement for some of that testing and the potential of billing insurance.

Tracing technology has been promising. Do you have any plans to tie tests to these applications to testing?

We've had several conversations with contact tracing apps and we continue to work in collaboration with public health departments in their contract tracing efforts. Having the test is obviously one thing, but you have to use the information to actually stem the tide of COVID infection. And so, it is an essential step in working closely with various people.

I do like the app-based models where you obviously want to maintain people's privacy, but having people opt-in to share their location history if they test positive so you can contact nearby people.

What does Curative do once there's a vaccine? Are you obsolete?

The U.S. needs to maintain some kind of spare capacity so that next time we are not having to build all of this during a pandemic. But we are a strange company because our goal is to essentially put ourselves out of business. Ultimately, and I say this to everyone we hire, we don't know how long this will go on for. We want to provide as many tests as needed, but the goal is to end COVID and not be doing COVID testing anymore.

Curative took off in March when you arrived in Los Angeles from Silicon Valley, how has the journey been for you personally?

I don't have very much free time, but it's been a lot of fun to be able to work at this pace and have the support of people like the city, the mayor's office to really just do what is needed to scale this up. When we work with suppliers, and we say we're doing COVID testing, they just move heaven and earth to make things happen. It's been really inspiring to be a part of that push forward.

We are just pushing as hard as we can to scale up as fast as we possibly can and bring on as much testing as we can. The city opening up testing to everybody is kind of a culmination of that. We're making about 50,000 kits a day right now and we want to make that as widely available as we can. I would like to get a little more sleep.

The interview has been edited for clarity and brevity.

Correction: An earlier version of this story stated that Curative's saliva tests have a 10% false positive rate. In actuality, the tests have a 10% false negative rate.

Do you have a story that needs to be told? My DMs are open on Twitter @racheluranga. You can also email me.

From Your Site Articles
Related Articles Around the Web
https://twitter.com/racheluranga
rachel@dot.la
The LA Startup Taking on One of Parenting’s Most Frustrating Problems

🔦 Spotlight

Hello Los Angeles,

Every parent knows the feeling of becoming an overnight expert in something they never wanted to learn.

For families navigating developmental delays, behavioral health needs, autism, speech therapy, occupational therapy or pediatric mental health support, that learning curve can become a full-time job. Finding the right specialist is hard enough. Getting those specialists, pediatricians, insurers and families to actually coordinate with each other? That’s often where the system breaks.

That’s the problem Los Angeles-based Village is trying to solve.

The specialty pediatrics startup raised $9.5 million in seed funding this week, led by Upfront Ventures, with participation from Bling Capital, GTMFund and Perceptive Ventures.

Its AI-powered platform is designed to bring families, providers, pediatricians and payers into one coordinated care system for children with developmental, behavioral and mental health needs.

The company was born out of co-founder Brandon Terry’s personal experience navigating care for his daughter after she was diagnosed with a rare genetic condition. Like many parents, his family faced long waitlists, high out-of-pocket costs and a fragmented web of specialists who were not necessarily working from the same playbook.

The pitch is not simply “find a provider faster.” Village wants to coordinate the entire team around a child, including occupational therapists, speech-language pathologists, behavioral therapists and pediatricians. Its AI agent, Vera, is designed to help with the administrative drag that often slows pediatric practices down: scheduling, documentation, billing and care coordination.

The company’s raise also points to a less flashy, but deeply consequential corner of health tech: making complex care easier to navigate. In specialty pediatrics, the pain point is not always the quality of care itself. It is the space between appointments, referrals, insurance approvals and provider communication where families are often left to connect the dots themselves.

So far, Village says it has built a network of more than 400 independent pediatric specialty providers in Southern California and has contracts with major commercial insurers including Blue Cross & Blue Shield, Cigna and UnitedHealthcare. The new funding will help the company expand across Southern California, into other parts of California and eventually into new states.

In other words, the next wave of healthcare infrastructure may not look like one giant hospital system. It may look more like a connected network built around the people who have been holding the system together all along: families.

And yes, in this case, it really does take a Village.

Venture deals follow below.👇


🤝 Venture Deals

    LA Companies

    • MOSH, the brain health nutrition brand co-founded by Maria Shriver and Patrick Schwarzenegger, raised a $13M Series A led by Main Street Advisors to expand nationally across grocery retailers and accelerate product innovation. The Los Angeles-based company plans to use the funding to grow its retail footprint, including an upcoming Target launch, while expanding its lineup of brain-focused nutrition products with new high-protein bars designed to support both cognitive and physical performance. - learn more
    • Spring Labs raised $5M to expand its AI-native compliance platform for banks and fintechs, with the funding led by BankTech Ventures and Haymaker Ventures. The Marina del Rey-based company is building AI agents that automate complaint handling, dispute resolution, and other compliance workflows, helping regulated financial institutions scale operations more efficiently while maintaining oversight and auditability. - learn more
    • FlowPrompt.ai secured a strategic seed investment from ART Fund SP, part of ChainBLX SPC, as the company expands its AI orchestration platform designed to help developers build and manage complex AI workflows through a visual interface. Alongside the investment, the companies also launched a global AI hackathon and builder program that will give selected founders access to funding opportunities, platform tools, and a live investor pitch event in Los Angeles later this summer. - learn more
    • Chance Studios raised $3.2M to build a unified platform for trading card game collectors, aiming to bring inventory management, marketplace activity, and community features into a single ecosystem. The round was co-led by Makers Fund and Hashed, with participation from Arbitrum Gaming Ventures, GAM3GIRL VC, and others, as the company looks to modernize how collectors buy, track, and interact around physical and digital TCG assets. - learn more

    LA Venture Funds
    • Rebel Fund participated in Moritz’s $9M seed round, backing the AI-native law firm as it looks to automate large portions of routine corporate legal work. The company combines software with experienced attorneys to speed up contract drafting and review, and says it has already handled more than $2 billion worth of contracts across over 100 companies since launching earlier this year. - learn more
    • Rebel Fund participated in Corvera’s $4.2M seed round, backing the AI-native supply chain platform as it automates back-office operations for consumer packaged goods brands. The Y Combinator-backed startup is building AI agents that can handle workflows like order processing, invoicing, and demand planning across fragmented enterprise systems, helping brands scale operations without significantly increasing headcount. - learn more
    • Chaac Ventures participated in Astrocade’s $5.6M funding round, backing the gaming startup as it builds a social gaming platform centered around community-created interactive experiences. The company is focused on blending gaming, streaming, and creator tools into a more collaborative entertainment platform, and plans to use the funding to expand development and grow its creator ecosystem. - learn more
    • Fusion VC participated in MSICS Pharma’s $3.6M funding round, backing the biotech company as it advances psilocybin-based treatments for PTSD, depression, and OCD. The company is developing medical-grade psychedelic compounds and plans to use the funding to expand production, accelerate clinical trials, and prepare for broader commercialization as interest in psychedelic therapies continues to grow. - learn more
    • JAM Fund participated in Fun’s $72M Series A, backing the payments infrastructure startup as it scales its platform for moving money across fintech and digital asset applications. The round was co-led by Multicoin Capital and SignalFire, and the company plans to use the funding to expand internationally, pursue acquisitions, and deepen its infrastructure stack as demand grows for faster global payment systems. - learn more

    LA Exits

    • Tapin2 was acquired by Greater Sum Ventures, joining MyVenue as part of GSV’s expanded point-of-sale technology platform for stadiums, arenas and live entertainment venues. Tapin2 provides self-service, suite catering and mobile ordering technology for high-volume sports and entertainment venues, while MyVenue offers cloud-native POS software across concessions, premium seating, retail, in-seat ordering and other venue operations. Together, the companies say their technology is used in more than 70% of MLB and NFL stadiums. Terms of the transaction were not disclosed. - learn more
    • Motiv Space Systems signed a definitive agreement to be acquired by Rocket Lab, bringing its space robotics, motion control systems and precision spacecraft mechanisms into Rocket Lab’s growing space systems business. Motiv’s technology has supported major missions including NASA’s Mars Perseverance rover and lunar rover programs, and the company will be rebranded as Rocket Lab Robotics after the deal closes, which is expected in the second quarter of 2026. - learn more
    • Robyn was acquired by Los Angeles-based Tot Squad, bringing its AI-powered doula tool into Tot Squad’s broader support platform for expecting and new moms. Robyn’s AI was trained on more than 70,000 de-identified messages between parents and doulas, and the acquisition will help Tot Squad offer free, around-the-clock pregnancy and early motherhood guidance alongside access to human experts like doulas, lactation consultants and sleep coaches. Terms of the deal were not disclosed. - learn more

      Download the dot.LA App

      Match Goes Niche With $100M Move

      🔦 Spotlight

      Hello Los Angeles,

      It’s May, and LA is about to have one of its more important weeks.

      The Milken Institute Global Conference 2026 returns to Beverly Hills next week, bringing together thousands of investors, operators, policymakers, and executives. It’s one of the few places where public markets, private capital, and tech actually overlap in the same rooms, and where you can usually get an early read on what capital is leaning into before it fully shows up in the data.

      This year, one theme is already starting to surface. Platforms are getting more specific, not more broad.

      This week’s news is a good example.

      Match Group is investing $100 million into Sniffies, a fast-growing, location-based platform built for gay, bi, trans, and queer men. It’s a notable move for a company best known for mainstream dating apps like Tinder and Hinge, and it signals a deeper push into more niche, community-driven platforms.

      Sniffies operates very differently from traditional dating apps. It’s more real-time, more map-based, and more focused on immediacy than long-term matching. In other words, it’s built around behavior, not profiles.

      And that’s what makes the investment interesting.

      For years, the dominant strategy in consumer platforms was scale, build one product that works for everyone. But what we’re seeing now is the opposite. The platforms that are gaining traction tend to be the ones that understand a specific audience deeply and build for how that group actually behaves.

      Match leaning into that shift isn’t just about expanding its portfolio. It’s a recognition that growth is coming from focus.

      And in a city like Los Angeles, that’s usually where things start.

      Below are this week’s venture deals and fund announcements across LA 👇


      🤝 Venture Deals

        LA Companies

        • Illuminant Surgical raised an $8.4M seed round to accelerate the rollout of its real-time anatomical projection platform, which aims to give surgeons enhanced visibility during procedures. The company’s “Skylight” system is designed to project internal imaging directly onto the patient, improving precision and reducing risk, and the funding will support product development and early commercialization efforts. - learn more
        • Jupid raised $840K in early funding to support its AI-native accounting platform, which is designed to automate bookkeeping, tax filing, and compliance for small businesses directly within banking platforms. The company is building what it describes as an embedded “AI accountant” that integrates with financial institutions to streamline operations for entrepreneurs, and plans to use the funding to expand partnerships and accelerate product development as demand grows for automated financial tools. - learn more
        • Lumicup raised a $4.38M Series A to expand its product line and scale manufacturing as it looks to meet growing demand for its consumer health and wellness products. The company plans to use the funding to increase production capacity, invest in new product development, and strengthen its distribution as it continues to grow its footprint in the market. - learn more
        • Counterpart raised a $50M Series C to expand its AI-driven “agentic insurance” platform, which helps small businesses manage growing legal and employment risks tied to AI adoption. The round was led by Valor Equity Partners with participation from existing investor Vy Capital, bringing the company’s total funding to $106M, and the capital will be used to launch new insurance products, expand risk management capabilities, and scale its underwriting platform. - learn more
        • Nervonik raised a $52.5M Series B to advance its next-generation peripheral nerve stimulation technology, which aims to deliver more precise, personalized treatment for chronic pain. The round was led by Amzak Health with participation from Elevage Medical Technologies, U.S. Venture Partners, Lumira Ventures, Foothill Ventures, and Shangbay Capital, and the company plans to use the funding to accelerate clinical programs and move toward commercialization. - learn more
        • LighthouseAI raised an $8M Series A to expand its AI-powered platform that helps pharmaceutical companies manage state licensing and regulatory compliance. The round was led by Boxcars Ventures with participation from TGVP and existing investors, and the company plans to use the funding to enhance product development, improve service delivery, and support continued growth as it scales across the pharma supply chain. - learn more

        LA Venture Funds
        • MANTIS Venture Capital participated in Rogo’s $75M Series C, backing the AI platform as it builds autonomous financial agents designed to streamline complex workflows for banks and investment firms. The round was led by Sequoia Capital and included a mix of major financial institutions and venture firms, signaling strong demand for AI tools that can augment decision-making across high-stakes finance. - learn more
        • M13 participated in Chord’s $7M funding round, backing the AI commerce platform as it builds a “context layer” designed to unify fragmented data, tools, and workflows for retail brands. The round was led by Equal Ventures with participation from Chingona Ventures and CEAS Investments, and the company aims to help operators move beyond dashboards toward systems that can make real-time decisions and automate actions across the business. - learn more
        • Fika Ventures participated in Lumian’s funding round, backing the startup as it launches an AI-native Amazon agency designed to automate and optimize how brands operate on the marketplace. The company is focused on replacing traditional agency workflows with AI-driven systems that can manage everything from advertising to operations in real time, reflecting a broader shift toward automation in e-commerce. - learn more
        • Riot Ventures co-led True Anomaly’s $650M Series D, backing the defense space startup as it scales spacecraft, software, and autonomous systems designed for national security missions in orbit. The round values the company at around $2.2 billion and brings total funding to over $1 billion since its 2022 founding, and the company plans to use the capital to accelerate mission deployments, expand manufacturing, and grow its workforce as demand increases for space-based defense capabilities. - learn more
        • Clocktower Technology Ventures participated in Clarasight’s $11.5M Series A, backing the AI-powered travel and expense platform as it works to unify fragmented enterprise data into a single system. The round was led by AlleyCorp with participation from several travel and fintech-focused investors, and the company plans to use the funding to expand product development and scale go-to-market efforts as demand grows for AI-driven efficiency in corporate travel. - learn more
        • Halogen Ventures and Mucker Capital participated in SkyfireAI’s $11M seed round, backing the startup as it builds an AI-native platform for coordinating autonomous, multi-drone operations. The company’s software is designed for public safety and defense use cases, helping teams deploy and manage fleets of drones with greater speed and efficiency without increasing staffing, and it plans to use the funding to accelerate product development, expand its team, and scale deployments with government and mission-critical customers as demand grows for autonomous drone systems. - learn more
        • Matter Venture Partners led OpenLight’s $50M Series A-1, with participation from Acclimate Ventures, Catapult Ventures, and existing investors, backing the photonics company as it scales its next-generation chip platform for AI infrastructure. The funding brings total capital raised to $84M and will be used to accelerate global deployment of its silicon photonics technology across data centers, telecom, and other high-bandwidth applications. - learn more
        • Alexandria Venture Investments participated in Fathom Therapeutics’ $47M Series A, backing the biotech startup as it applies quantum chemistry and AI to design next-generation small molecule drugs. The oversubscribed round was led by Sutter Hill Ventures with participation from Chemistry and other investors, and the company plans to advance its platform, which simulates protein behavior inside living cells to accelerate drug discovery. - learn more

          Download the dot.LA App

          Netflix Doubles Down on LA

          🔦 Spotlight

          Hey Los Angeles.

          Goodbye Coachella, hello Stagecoach. The desert doesn’t stay quiet for long, and neither does LA’s entertainment machine.

          This week, that momentum showed up in a more permanent way.

          Netflix is expanding its footprint in Los Angeles with a major move to take over and invest in Radford Studio Center, a historic production lot in Studio City. The company is planning a long-term transformation of the site, with upgrades to soundstages, production offices, and infrastructure designed to support the next generation of film and television production.

          It’s a notable shift in a moment when production has been under pressure in California, with studios increasingly looking outside the state for cost advantages. Netflix going deeper in LA, and specifically into a legacy studio lot, signals a different kind of commitment. Not just to content, but to where that content actually gets made.

          And it comes at a time when the streaming wars have matured. Growth is harder, budgets are tighter, and the focus has shifted from scale at all costs to efficiency and control. Owning or operating more of the production environment gives Netflix tighter control over timelines, costs, and output.

          For Los Angeles, it’s a reminder of what still anchors the city. Even as AI, defense tech, and infrastructure startups continue to rise, entertainment remains one of the few industries where LA isn’t just competitive, it’s foundational.

          Different headlines each week, but a consistent theme underneath them. Whether it’s power, autonomy, or content, the companies that matter are investing in the layers they don’t want to outsource.

          And in this case, that layer is Hollywood itself.

          Below are this week’s venture deals, fund announcements, and acquisitions across LA 👇


          🤝 Venture Deals

            LA Venture Funds

            • UP Partners and Calm Ventures participated in Reliable Robotics’ $160M funding round, backing the autonomous aviation company as it advances pilotless flight technology for cargo and passenger aircraft. The round included a mix of new and existing investors, and the company plans to use the capital to accelerate certification efforts and expand deployment of its autonomous systems across commercial aviation. - learn more
            • Blue Heron Ventures participated in Tava Health’s $40M Series C, backing the company as it expands its tech-enabled mental health platform into a more integrated, full-stack system for providers, employers, and health plans. The round was led by Centana Growth Partners with participation from existing investors, and the company plans to use the funding to roll out new AI-powered tools and broaden access to care while reducing administrative friction across the system. - learn more
            • Vamos Ventures participated in Zócalo Health’s $15M Series A, backing the company as it scales its tech-enabled, community-based primary care model focused on high-need and underserved populations. The round was led by .406 Ventures with participation from existing and new investors, and the company plans to use the funding to expand its clinics and deepen partnerships with Medicaid programs as demand for accessible care grows. - learn more

            LA Exits
            • Studio71 has been acquired by Fixated as part of a broader deal in which German media company ProSiebenSat.1 sold its North American creator business, giving Fixated a large-scale network of creators and podcast operations and significantly expanding its footprint as it continues an aggressive roll-up strategy in the creator economy. The move signals continued consolidation in the space, with Fixated building a more vertically integrated platform across talent management, content production, and distribution. - learn more
            • Bonsai Health has been acquired by ModMed, bringing its AI-powered patient engagement platform into a broader healthcare software ecosystem. The deal is aimed at integrating Bonsai’s “agentic AI” capabilities into ModMed’s platform to automate patient outreach, fill care gaps, and improve scheduling across a network of nearly 50,000 providers. - learn more

              Download the dot.LA App

              RELATEDEDITOR'S PICKS
              Trending